Conclision
To the best of our knowledge, this is the first report describing the use of famitinib and camrelizumab as a neoadjuvant treatment for ATC with wild‐type BRAF. Clinical trial for a novel neoadjuvant approach for ATC are currently open for enrollment.
Shuwen Yang, Dongmei Ji, Fen Xue are co‐first authors.